Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.

@article{Sassa2011AberrantPM,
  title={Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.},
  author={Miho Sassa and Yoshitaka Hayashi and Reiko Watanabe and Toyone Kikumori and Takatoshi Imai and Junichi Kurebayashi and Tetsuya Kiuchi and Yoshiharu Matsuura Murata},
  journal={Thyroid : official journal of the American Thyroid Association},
  year={2011},
  volume={21 5},
  pages={
          511-7
        }
}
BACKGROUND More than 80% of all thyroid cancers, the most common endocrine malignancy, are papillary thyroid cancer (PTC). It is well established that CITED1 (Cbp/p300 Interacting Transactivators with glutamic acid [E] and aspartic acid [D]-rich C-terminal domain) mRNA is characteristically overexpressed in PTC. Our previous study suggested a positive association of BRAF mutation with CITED1 overexpression. However, the mechanism of CITED1 expression in PTC remains to be elucidated. In the… CONTINUE READING
BETA